New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2013
12:08 EDTSVNTQSavient receives approval to sell substantially all assets to Crealta
Savient Pharmaceuticals has received approval from the U.S. Bankruptcy Court for the District of Delaware to sell substantially all of the assets of Savient, including all KRYSTEXXA assets, to Crealta Pharmaceuticals LLC. As previously announced, Savient and Crealta have entered into an acquisition agreement through which Crealta would acquire substantially all of the assets of Savient for gross proceeds of approximately $120.4M. The agreement was reached following an auction conducted pursuant to bidding procedures approved by the Court. According to the terms of the acquisition agreement, Crealta will purchase Savient's pharmaceutical portfolio, which is highlighted by the chronic refractory gout drug KRYSTEXXA. Crealta was established in August in partnership with GTCR. Having received approval from the Court, the transaction remains subject to certain closing conditions and the termination of the waiting period under Hart-Scott-Rodino.
News For SVNTQ From The Last 14 Days
Check below for free stories on SVNTQ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SVNTQ

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use